Avian influenza
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- Infection of domestic and wild fowl and other birds with influenza A virus. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic poultry.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Avian influenza
- Alternative names
- avian influenza
- Therapeutic area
- Infectious Disease
- Disease mechanisms
- Acquired
Sources for recorded values
- Severity
- Unknown
- Infectious Disease
- Pulmonology
Sources for recorded values
- MONDO ID
- MONDO:0018695
- Parent condition
- MONDO:0005812
Related records
Broader conditions (12)
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Influenza
- Primary viral infectious disease
- Respiratory system disorder
- Respiratory tract infectious disorder
- Viral infectious disease
- Viral respiratory tract infection
Trials (100)
- 2013/2017 H7N9 Prime-Boost Interval
- 2017 A/H7N9 IIV Revaccination
- A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
- A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
- A Retrospective, Observational Registry of Participants With Avian Influenza Infection
- A Safety and Immunogenicity Study of IVACFLU-A/H5N1
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
- A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
- A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
- A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
- A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
- A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
- A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
- A/H5N1 Vaccine in Healthy Children Aged 2-9 Years
- An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...
- Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
- Avian Influenza Studies In Lebanon
- Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
Drugs in development (5)
- Aluminum hydroxide Phase 2
- Imiquimod Phase 1
- Influenza virus vaccine Phase 3
- Oseltamivir Phase 2
- Probenecid Phase 1